Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab.
Kimberly M LauIla M SaundersAaron M GoodmanPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)
Extramedullary relapse occurs frequently following treatment of B-ALL with blinatumomab. Further studies aimed at preventing extramedullary relapse following blinatumomab treatment are warranted.